Stockhead on MSN
Alterity delivers encouraging phase II data in MSA trial
Alterity Therapeutics’ phase II study of its lead compound ATH434 in multiple system atrophy (MSA) has been featured in an ...
Data highlights symptom stability and enhanced efficacy signals in higher dose group –– Analysis offers valuable insights to guide ongoing ...
YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability ...
A school community is rallying behind a former teacher who has been diagnosed with a rare and life-limiting condition ...
An update from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics presented promising data on ATH434 at the 36th ...
Q3 2025 Earnings Call November 10, 2025 5:00 PM ESTCompany ParticipantsRick Winningham - CEO & DirectorRhonda Farnum ...
Q3 2025 Earnings Call Transcript November 10, 2025 Wave Life Sciences Ltd. misses on earnings expectations. Reported EPS is $ ...
5d
Using Skin Biopsy Technology, CND Life Sciences Performs the 50,000th Syn-One Test(R) for Patients
Launched in 2019, the Syn-One Test is used by neurologists and other clinicians in all 50 states to aid in the diagnosis of synucleinopathies SCOTTSDALE, Ariz., /PRNewswire/ -- CND Life Sciences (CND) ...
Roche’s fenebrutinib shows unprecedented positive phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis ...
The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomideIn a pivotal PPMS study ...
Weakened lung function diagnosis can potentially be achieved sooner in the aging process with increased monitoring.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback